VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Vistagen Therapeutics, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.20+0.00 (+1.55%)
Close on Oct 19, 2026
- Market cap
- $8.73M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.8469 (−94.99%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Vistagen Therapeutics, Inc. reported revenue of $2.50M for the twelve months to Jun 30, 2026.
Revenue
$2.50M
TTM Q1 2027
Operating income
-$69.66M
TTM Q1 2027
EPS, diluted
-$1.67
TTM Q1 2027
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $8.73M
- P/E ratio
- –
- Price to sales
- 3.49
- Price to book
- 0.36
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $2.50M
- Net income
- -$67.62M
- EPS, diluted
- -$1.67
- Book value per share
- $0.57
- Diluted shares
- 43M
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
$2.50M
Operating income
-$69.66M
Net income
-$67.62M
EPS, diluted
-$1.67
Free cash flow
–
Reported periodTrailing twelve months